ANTIGENICS CEO RECEIVES HUMANITARIAN AWARD FROM THE SABIN VACCINE INSTITUTE
Business Wire
Jun 29, 2006
Antigenics Inc. (NASDAQ: AGEN) today announced that the Sabin Vaccine
Institute has awarded the company’s chairman and CEO, Garo H. Armen,
PhD, the 2006 Sabin Humanitarian Award. The Albert B. Sabin Annual
Awards recognize extraordinary figures in biotechnology, medical
research and medical reporting, and were celebrated at a gala, themed
"Celebrating Hope for a Healthier World," in New York City last night.
"In each case, these extraordinary individuals didn’t settle for high
achievement in just one area, but they broadened their horizons and
multiplied their effect," said H. R. Shepherd, DSc, chairman of the
Sabin Vaccine Institute.
"They each found new ways to further medical science, reaching out
to help a greater cross-section of humanity."
Dr. Armen cofounded Antigenics in 1994 with Pramod K. Srivastava,
PhD. Dr. Armen is also the founder and chairman of the Children of
Armenia Fund, a charitable organization established in 2000 that
is dedicated to the positive development of the children and youth
of Armenia. From mid-2002 through 2004, Dr. Armen also served as
chairman of the board of directors of the pharmaceutical company
Elan Corporation. He received a PhD in physical chemistry from the
Graduate Center, City University of New York.
About the Albert B. Sabin Vaccine Institute
The Albert B. Sabin Vaccine Institute is a public, nonprofit
organization dedicated to continuing the work of Dr. Albert Sabin,
who envisioned the enormous potential of vaccines to prevent
deadly disease. The Sabin Vaccine Institute (SVI) promotes rapid
scientific advances in vaccine development, delivery and distribution
worldwide. SVI’s Cancer Vaccine Consortium provides a mechanism for
collaborative activity to speed the research, regulatory process and
delivery of new cancer vaccines to the market.
The SVI grants annual Sabin Awards to honor individuals for their
extraordinary and ongoing contributions, and generosity of spirit
inspiring humanitarian actions. Their personal life and public work
exemplify the best of human kindness, and their continuous efforts
to alleviate suffering inspire hope for the greater good of all.
About Antigenics
Antigenics is a biotechnology company working to develop treatments
for cancers, infectious diseases and autoimmune disorders. For more
information, please visit Inc. Media
Relations: Sunny Uberoi, 212-994-8206 suberoi@antigenics.com Investor
Relations: Shalini Sharp, 800-962-2436 ir@antigenics.com .